EMEA Widening of acceptance limit [Regulatives / Guidelines]

posted by mittyri  – Russia, 2015-02-03 14:16 (4145 d 21:35 ago) – Posting: # 14363
Views: 3,208

Dear Dr.Dan & All,

I apologize for leveling up so old thread, but I didn't find any additional topics.

❝ IMHO you just have to point out in the protocol that the drug has no narrow therapeutic window and that a slightly higher variability of Cmax will not raise any safety concerns.

Is it really enough as sound clinical justification? It doesn't look so...
Can someone help with additional requirements or examples?

PS: The link to the presentation above is broken :-(

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
237 visitors (0 registered, 237 guests [including 23 identified bots]).
Forum time: 12:51 CEST (Europe/Vienna)

There are no dangerous thoughts;
thinking itself is dangerous.    Hannah Arendt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5